- Novel therapeutic agents that have fast onset of action, good safety and tolerability profiles, and that address common co-morbidities (for example, anxiety and substance abuse)
- Glutamatergic modulators
- Neuroactive cytokines
- Molecules that positively impact synaptic plasticity and cellular resilience
- Phase 2 and later-stage opportunities with defined mechanism of action and superior efficacy over standard of care
| - Novel therapeutic agents that provide rapid improvement in bipolar depression and in suicidal patients and that produce long-term stabilization of mood and prevent recurrences
| - Predictive biomarkers of response to antidepressants
- Biomarkers for relapse prediction
- Diagnostic biomarkers to identify subgroups with different etiologies
|
